Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Non-Current Liabilities (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Total Non-Current Liabilities for 12 consecutive years, with $344.9 million as the latest value for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities rose 4.16% year-over-year to $344.9 million; the TTM value through Mar 2026 reached $344.9 million, up 4.16%, while the annual FY2025 figure was $345.0 million, 3.55% up from the prior year.
  • Total Non-Current Liabilities hit $344.9 million in Q1 2026 for Syndax Pharmaceuticals, roughly flat from $345.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $345.0 million in Q4 2025 and bottomed at $2000.0 in Q3 2024.
  • Average Total Non-Current Liabilities over 5 years is $119.9 million, with a median of $1.1 million recorded in 2023.
  • Year-over-year, Total Non-Current Liabilities crashed 99.77% in 2024 and then soared 16108650.0% in 2025.
  • Syndax Pharmaceuticals' Total Non-Current Liabilities stood at $722000.0 in 2022, then dropped by 18.56% to $588000.0 in 2023, then surged by 56556.97% to $333.1 million in 2024, then rose by 3.55% to $345.0 million in 2025, then dropped by 0.03% to $344.9 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $344.9 million, $345.0 million, and $322.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.